Physician profile
Doan DO
NPI 1649420589
$5,156.65
in general payments reported to CMS, 2019-2025
35 companies · $898 in 2025
The $898 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $689 · 2021: $680 · 2022: $526 · 2023: $834 · 2024: $896 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,628.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,115.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $588.41 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $550.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $535.04 | 2019-2025 | |
| Abbvie INC. | $427.45 | 2021-2025 | Qulipta, Ubrelvy |
| Merck Sharp & Dohme LLC | $243.88 | 2019-2021 | |
| Glaxosmithkline, LLC. | $229.91 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $176.89 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $156.88 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $155.55 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $103.38 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.35 | 2021-2025 | Xifaxan, Trulance |
| Allergan, INC. | $66.12 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $62.48 | 2021 | |
| Sanofi-Aventis U.S. LLC | $61.65 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $50.60 | 2022 | |
| Sanofi Pasteur INC. | $47.68 | 2019-2023 | |
| Gilead Sciences, INC. | $45.57 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $44.39 | 2023 | |
| Merit Medical Systems INC | $43.99 | 2025 | Esophyx |
| Hologic Sales and Service, LLC | $42.46 | 2022-2023 | Aptima |
| Dexcom, INC. | $41.76 | 2024-2025 | Dexcom G6 Transmitter |
| Cranial Technologies, INC | $41.31 | 2019-2021 | |
| Phadia US INC. | $36.38 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.71 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $28.55 | 2021 | |
| Dynavax Technologies Corporation | $26.19 | 2024 | Heplisav-B |
| Neos Therapeutics, Lp | $21.24 | 2019 | |
| Shield Therapeutics INC | $16.93 | 2023 | Accrufer |
| Genentech USA, INC. | $16.33 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.62 | 2024 | Nuzyra |
| Mylan Specialty L.P. | $12.18 | 2019 | |
| Eisai INC. | $12.03 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.95 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doan DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.